论文部分内容阅读
目的探讨帕罗西汀治疗脑卒中后抑郁症的临床疗效和安全性。方法选取2010年9月—2012年3月于徐州市电力医院就诊的73例脑卒中后抑郁症患者,随机分为对照组34例和治疗组39例。对照组给予常规神经系统药物及对症支持治疗,治疗组在对照组基础上给予帕罗西汀治疗,比较两组患者的临床疗效及治疗前后的神经功能缺损(NIHSS)评分、抑郁自评量表(SDS)评分、生活质量评定量表(ADL)评分、汉密尔顿抑郁量表(HAMD)评分。结果治疗组总有效率(92.3%)高于对照组(70.6%),治疗后SDS、NIHSS、HAMD评分低于对照组,ADL评分高于对照组,躯体功能、生理功能、社会功能、物质生活得分均高于对照组,差异均有统计学意义(P<0.05)。结论帕罗西汀治疗脑卒中后抑郁症具有显著疗效,可明显改善患者焦虑、抑郁情绪,安全性高。
Objective To investigate the clinical efficacy and safety of paroxetine in the treatment of post-stroke depression. Methods Seventy-three post-stroke depression patients from September 2010 to March 2012 in Xuzhou Power Hospital were randomly divided into control group (n = 34) and treatment group (n = 39). The control group was given conventional neurological drugs and symptomatic supportive treatment. The treatment group was treated with paroxetine on the basis of the control group. The clinical efficacy, NIHSS score, depression self-rating scale (SDS) ) Score, the quality of life rating scale (ADL) score, the Hamilton Depression Rating Scale (HAMD) score. Results The total effective rate (92.3%) in the treatment group was higher than that in the control group (70.6%). After treatment, the scores of SDS, NIHSS and HAMD were lower than those of the control group, and the ADL score was higher than that of the control group (body function, physiological function, social function, Scores were higher than the control group, the differences were statistically significant (P <0.05). Conclusions Paroxetine has significant curative effect on post-stroke depression and can significantly improve anxiety and depression of patients with high safety.